☆ 4.3 Article

Establishing a novel Fanconi anemia signaling pathway-associated prognostic model and tumor clustering for pediatric acute myeloid leukemia patients

OPEN MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Comprehensive molecular understanding of pediatric acute myeloid leukemia

Norio Shiba

Summary: Pediatric acute myeloid leukemia (AML) is a diverse disease with different genetic abnormalities. Fusion genes like RUNX1::RUNX1T1, CBFB::MYH11, and KMT2A::MLLT3 are commonly found in pediatric AML cases, while FLT3-internal tandem duplication, CEBPA-bZip, and NPM1 mutations are detected in a smaller percentage of cases. Unlike in adults, mutations in DNMT3A, TET2, and IDH are rare in pediatric AML. Accurate risk assessment and treatment intensity require genome analysis to be done quickly and inexpensively, and the results should be given to patients in real-time. The presence or absence of minimal residual disease, as well as considering genetic abnormalities, are important factors in predicting prognosis and forming treatment strategies for AML. Development and clinical application of new targeted therapies based on identified genetic abnormalities require further exploration to determine the most effective drug combinations and timing.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches

Natasa Tosic et al.

Summary: Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy that accounts for 20% of pediatric leukemia cases. While overall survival rates have improved, AML remains a leading cause of mortality in pediatric cancers. Targeted therapy approaches and advances in genomic techniques have identified novel therapeutic targets and provided potential for significant clinical benefits in pediatric AML.

BIOCHEMICAL PHARMACOLOGY (2023)

Add to Collection

Review Immunology

Type-I Interferon Signaling in Fanconi Anemia

Karima Landelouci et al.

Summary: Fanconi Anemia (FA) is a genome instability syndrome caused by mutations in repair genes, leading to congenital abnormalities, premature aging, and bone marrow failure. There is a close relationship between genome instability, inflammation, and the production of type-I Interferon. Understanding the molecular mechanisms of type-I Interferon activation in FA may lead to the discovery of therapeutic targets for the associated inflammation and premature aging.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)

Add to Collection

Review Hematology

A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis

Anna Gueiderikh et al.

Summary: Described by Guido Fanconi almost 100 years ago, Fanconi anemia (FA) is a rare genetic disease characterized by developmental abnormalities, bone marrow failure (BMF) and cancer predisposition. The proteins encoded by FA-mutated genes and assembled in the FANC/BRCA pathway have key functions in DNA repair and replication safeguarding. Recent findings have revealed additional roles of FANC proteins in nucleolar homeostasis and ribosome biogenesis, impacting cellular proteostasis.

BLOOD REVIEWS (2022)

Add to Collection

Article Health Care Sciences & Services

Fanconi Anemia Pathway in Colorectal Cancer: A Novel Opportunity for Diagnosis, Prognosis and Therapy

Fatemeh Ghorbani Parsa et al.

Summary: Colorectal cancer (CRC) is the third most commonly diagnosed malignancy globally. This article explores the role of Fanconi anemia (FA) genes in CRC susceptibility, as mutations in these genes increase the risk of tumor development. The FA pathway is involved in DNA repair and genome stability, and has been associated with CRC progression and drug resistance. FANC genes have the potential to serve as promising prognostic and predictive biomarkers in CRC management and treatment, as well as targets for precision cancer medicine.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia

Piotr Obszanski et al.

Summary: Acute myeloid leukemia (AML) comprises 15-20% of childhood leukemia cases, with a survival rate of not exceeding 82% and 5-year event-free survival rates ranging from 46% to 69%. The disease is influenced by multiple mutations and epigenetic changes, affecting treatment susceptibility and relapse rate. Molecular-targeted therapies have been developed and studied in clinical trials to address these challenges, originally introduced in adult AML and now gradually changing the therapeutic approach to pediatric AML. Research involving larger pediatric populations is needed to further improve outcomes.

MOLECULES (2022)

Add to Collection

Review Medicine, General & Internal

Advances in acute myeloid leukemia

Laura F. Newell et al.

Summary: AML, a rare and potentially catastrophic diagnosis, has seen recent advancements in personalized therapy and novel treatment options due to discoveries of molecular drivers of the disease.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Hematology

A novel 4-mRNA signature predicts the overall survival in acute myeloid leukemia

Zizhen Chen et al.

Summary: The study identified 336 differentially expressed genes between AML and control samples, as well as 206 genes representing intratumor heterogeneity of AML. By utilizing a LASSO Cox regression model, a 4-mRNA prognostic signature was established, showing significant association with shorter overall survival, complex karyotype, and adverse mutations. Validation in independent cohorts confirmed its predictive value independent of traditional prognostic factors.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Review Hematology

How I treat pediatric acute myeloid leukemia

Jeffrey E. Rubnitz et al.

Summary: Treatment outcomes for pediatric patients with acute myeloid leukemia (AML) are behind those with acute lymphoblastic leukemia (ALL) due to disease heterogeneity, lack of targeted therapies, and slow development of immunotherapy. Further intensification of conventional chemotherapy is unlikely to reduce relapse rates, but comprehensive genomic analyses and understanding of leukemic stem cells may lead to more effective tailored therapies in the future. New therapies like venetoclax and CAR T-cell therapy offer hope for improved outcomes in pediatric AML treatment.

BLOOD (2021)

Add to Collection

Article Oncology

A Novel 85-Gene Expression Signature Predicts Unfavorable Prognosis in Acute Myeloid Leukemia

Yanli Lai et al.

Summary: The study aimed to develop a novel gene profile to classify AML patients into different survival probability subgroups, using data from 405 patients and validated in TCGA. The 85-gene score was found to be superior in predicting AML patient prognosis compared to 2 established gene signatures. It successfully stratified AML patients into 3 subgroups with different survival probabilities based on hierarchial clustering of gene expression levels.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2021)

Add to Collection

Article Oncology

Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia

Li-Peng Liu et al.

CANCER MEDICINE (2020)

Add to Collection

Article Hematology

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia

Tobias Herold et al.

HAEMATOLOGICA (2018)

Add to Collection

Article Hematology

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia

Tobias Herold et al.

HAEMATOLOGICA (2018)

Add to Collection

Article Oncology

Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Cancer Surveillance in Fanconi Anemia

Sharon A. Savage et al.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2018)

Add to Collection

Review Medicine, General & Internal

Acute myeloid leukaemia

Nicholas J. Short et al.

LANCET (2018)

Add to Collection

Article Multidisciplinary Sciences

Functional genomic landscape of acute myeloid leukaemia

Jeffrey W. Tyner et al.

NATURE (2018)

Add to Collection

Review Oncology

Fanconi anaemia and cancer: an intricate relationship

Grzegorz Nalepa et al.

NATURE REVIEWS CANCER (2018)

Add to Collection

Article Pediatrics

Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia

Hilda Ding et al.

PEDIATRIC TRANSPLANTATION (2017)

Add to Collection

Review Biochemistry & Molecular Biology

FANCD2 and DNA Damage

Manoj Nepal et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

Add to Collection

Article Medicine, Research & Experimental

Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia

Kerstin Knies et al.

JOURNAL OF CLINICAL INVESTIGATION (2017)

Add to Collection

Article Biochemistry & Molecular Biology

RFWD3-Mediated Ubiquitination Promotes Timely Removal of Both RPA and RAD51 from DNA Damage Sites to Facilitate Homologous Recombination

Shojiro Inano et al.

MOLECULAR CELL (2017)

Add to Collection

Review Oncology

Fanconi Anemia Signaling and Cancer

Manoj Nepal et al.

TRENDS IN CANCER (2017)

Add to Collection

Review Hematology

Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia

Nicholas E. Mamrak et al.

BLOOD REVIEWS (2017)

Add to Collection

Review Cell Biology

The Fanconi anaemia pathway: newyplayers and new functions

Raphael Ceccaldi et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Biochemical Research Methods

GOplot: an R package for visually combining expression data with functional analysis

Wencke Walter et al.

BIOINFORMATICS (2015)

Add to Collection

Review Hematology

Stress and DNA repair biology of the Fanconi anemia pathway

Simonne Longerich et al.

BLOOD (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Jianjiong Gao et al.

SCIENCE SIGNALING (2013)

Add to Collection

Article Biotechnology & Applied Microbiology

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

Guangchuang Yu et al.

OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)

Add to Collection

Editorial Material Oncology

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Ethan Cerami et al.

CANCER DISCOVERY (2012)

Add to Collection

Article Biochemical Research Methods

ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking

Matthew D. Wilkerson et al.

BIOINFORMATICS (2010)

Add to Collection

Review Medicine, General & Internal

MECHANISMS OF DISEASE Susceptibility Pathways in Fanconi's Anemia and Breast Cancer

Alan D. D'Andrea

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Cell Biology

Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia

Sudit S. Mukhopadhyay et al.

JOURNAL OF CELL BIOLOGY (2006)

Add to Collection

Review Biochemistry & Molecular Biology

Fanconi anemia (cross)linked to DNA repair

LJ Niedernhofer et al.

CELL (2005)

Add to Collection

Article Multidisciplinary Sciences

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

A Subramanian et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.